Certara (CERT) – Research Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Certara (NASDAQ: CERT) in the last few weeks:

• 3/6/2026 – Certara had its “equal weight” rating reaffirmed by Barclays PLC. They now have a $8.00 price target on the stock.
• 2/27/2026 – Certara had its price target lowered by Barclays PLC from $13.00 to $8.00. They now have an “equal weight” rating on the stock.
• 2/27/2026 – Certara was downgraded by Craig Hallum from “buy” to “hold”. They now have a $10.00 price target on the stock.
• 2/26/2026 – Certara had its “buy” rating reaffirmed by TD Cowen.
• 2/26/2026 – Certara had its “outperform” rating reaffirmed by Leerink Partners. They now have a $10.00 price target on the stock.
• 2/15/2026 – Certara was downgraded by Wall Street Zen from “buy” to “hold”.
• 2/7/2026 – Certara was upgraded by Wall Street Zen from “hold” to “buy”.

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.